Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neuromodulators for irritable bowel syndrome in a multicenter real-world cohort study in China
ChiCTR2400084241Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2024
- Modality
- Small Molecules, Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of escitalopram, paroxetine, sertraline, duloxetine, mirtazapine and 1 more in irritable bowel syndrome (IBS) (6 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Clinical efficacy rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
escitalopramparoxetinesertralineduloxetinemirtazapine
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on ChiCTR2400084241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084241.